Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25270196 | 0.96 | EGFR (0.40) | EGFRERBB2MAP4K4TGFBR1AURKB | |
| SCHEMBL25221506 | 0.93 | EGFR (0.40) | EGFRERBB2MAP4K4TGFBR1AURKB | |
| SCHEMBL25252805 | 0.93 | EGFR (0.45) | EGFRERBB2MAP4K4TGFBR1AURKB | |
| SCHEMBL25247218 | 0.90 | EGFR (0.54) | EGFRERBB2MAP4K4TGFBR1AURKB | |
| SCHEMBL30430009 | 0.90 | EGFR (0.54) | EGFRERBB2MAP4K4TGFBR1AURKB | |
| SCHEMBL30428769 | 0.90 | EGFR (0.43) | EGFRERBB2MAP4K4TGFBR1 | |
| SCHEMBL25211108 | 0.90 | EGFR (0.46) | EGFRERBB2TGFBR1AURKB | |
| SCHEMBL25254198 | 0.90 | EGFR (0.43) | EGFRERBB2MAP4K4TGFBR1 | |
| SCHEMBL29382670 | 0.90 | EGFR (0.46) | EGFRERBB2TGFBR1AURKB | |
| SCHEMBL25213282 | 0.90 | EGFR (0.43) | EGFRERBB2MAP4K4TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271936-A1 | EFGR INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| US-20230271936-A1 | EFGR INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| US-20230271936-A1 | EFGR INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| EP-4194443-A1 | EFGR INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2023-06-14 | — | — | EP | disclosed |
| EP-4194443-A1 | EFGR INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2023-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271936-A1 | EFGR INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | EGFR, WEE1, WEE2 | EGFR 1/4885ERBB2 5/4885MAP4K4 2579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.